The state of Florida currently has 48 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590
Recruiting
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive L... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
05/23/2025
Locations: K2 Medical Research, LLC, Maitland, Florida +1 locations
Conditions: Alzheimer Disease
Register for Updates
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/23/2025
Locations: JEM Research Institute, Atlantis, Florida +16 locations
Conditions: Alzheimer Disease
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/22/2025
Locations: JEM Research Institute, Atlantis, Florida +45 locations
Conditions: Alzheimer Disease
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/22/2025
Locations: Neurology of Central Florida, Altamonte Springs, Florida +60 locations
Conditions: Alzheimer Disease, Early Onset
Register for Updates
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
05/22/2025
Locations: JEM Research LLC, Atlantis, Florida +12 locations
Conditions: Preclinical Alzheimer's Disease
Register for Updates
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014
Recruiting
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Pos... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
05/19/2025
Locations: SFM Clinical Research, Boca Raton, Florida +10 locations
Conditions: Early Alzheimers Disease
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
05/16/2025
Locations: JEM Research Institute, Atlantis, Florida +12 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
Late Onset Alzheimer's Disease
NCT05010603
Recruiting
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/15/2025
Locations: University of Miami, Miami, Florida
Conditions: Alzheimer Disease
Register for Updates
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/15/2025
Locations: Genesis Trust Research Group, Atlantis, Florida +39 locations
Conditions: Alzheimer Disease
Register for Updates
Pulsed Electromagnetic Field Treatment With Dementia Patients
NCT06862557
Recruiting
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
05/15/2025
Locations: University of Miami, Boca Raton, Florida
Conditions: Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Register for Updates
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
NCT06546995
Recruiting
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/14/2025
Locations: Neumora Investigator Site, Bradenton, Florida +9 locations
Conditions: Alzheimer's Disease, Healthy Elderly
Register for Updates
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
NCT03649724
Recruiting
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.
Gender:
FEMALE
Ages:
Between 60 years and 120 years
Trial Updated:
05/12/2025
Locations: University of Miami Miller School of Medicine, Boca Raton, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment
Register for Updates